Diabetes: Page 7
-
Courtesy of Insulet Corp.
Insulet raises revenue forecast as Omnipod 5 drives US growth
Insulet is confident it can grow the market for tubeless insulin pumps in the long term, an outlook the company bases on its device’s convenience.
By Elise Reuter • May 5, 2023 -
Courtesy of Tandem Diabetes
Tandem expects to meet ‘key’ goals even as rival’s device launch may curb short-term sales growth
Tandem claims it has a better insulin pump than Medtronic’s recently approved rival MiniMed 780G device.
By Nick Paul Taylor • May 4, 2023 -
Courtesy of Dexcom
Dexcom proposes $1.1B debt offering to add to existing $2.6B cash reserve
About $189 million of the funds will go toward the repurchase of Dexcom stock and a portion will support other financial transactions, the company said.
By Nick Paul Taylor • May 3, 2023 -
Permission granted by Medtronic
Medtronic’s US diabetes business is floundering. Can the MiniMed 780G rescue it?
The company, sidelined by a warning letter while competitors brought new products to market, is counting on its newest diabetes devices to spur “pent up interest.”
By Elise Reuter • May 2, 2023 -
Courtesy of Dexcom
Dexcom reports ‘growing momentum’ behind G7 launch in first quarter
The CGM launch helped the company add more users than in any other quarter in its history.
By Nick Paul Taylor • April 28, 2023 -
Courtesy of Medtronic
Medtronic diabetes warning letter lifted by FDA
The resolution will allow Medtronic to bring new products to market faster, such as its new continuous glucose monitor, Simplera.
By Elise Reuter • April 25, 2023 -
Permission granted by Insulet
Insulet gets FDA clearance for tubeless pump to eliminate daily shots for basal insulin users
The device, called Omnipod GO, eliminates the need for daily injections for people with Type 2 diabetes, CEO Jim Hollingshead said.
By Elise Reuter • April 25, 2023 -
FatCamera via Getty Images
Know Labs hopes to advance non-invasive glucose sensor with proof-of-concept test
The company wants to use its Bio-RFID technology for glucose monitoring, and recently showed the device could detect and quantify specific molecules in water.
By Nick Paul Taylor • April 25, 2023 -
Courtesy of Medtronic
Medtronic wins FDA approval for long-delayed MiniMed 780G insulin pump
Analysts called the FDA approval a “positive” for Medtronic that “should somewhat aid in a turnaround of its U.S. diabetes franchise.”
By Nick Paul Taylor • April 24, 2023 -
Courtesy of Nevro
Nevro names Hologic exec as CEO
Kevin Thornal will take the reins from current CEO D. Keith Grossman, who will retire next week.
By Elise Reuter • April 20, 2023 -
Permission granted by Abbott
Abbott boosts organic sales outlook as device demand accelerates
A rebound in surgical procedure volumes as hospital staffing improved at the start of the year partially offset a steep drop in COVID-19 testing sales.
By Susan Kelly • April 19, 2023 -
Permission granted by Abbott
Abbott gets clearance for Libre 3 reader, opening path to Medicare coverage
With a standalone reader, Abbott said it is working to make the FreeStyle Libre 3 system available to people covered by Medicare.
By Elise Reuter • April 17, 2023 -
echoevg via Getty Images
Proxy adviser backs diabetes device developer Sernova in fight against activist investors
Institutional Shareholders Services said the activist investors “failed to present a detailed explanation” of their case and recommended that shareholders vote for Sernova’s director nominees.
By Nick Paul Taylor • April 17, 2023 -
Pixelseffect via Getty Images
Sernova defends record after investors attack ‘sluggish’ progress of regenerative medicine implant
The investors accused Sernova’s board of “complacently” overseeing “a period of eroding shareholder value.”
By Nick Paul Taylor • April 7, 2023 -
Retrieved from Abbott on April 06, 2023
Abbott faces Class I recall of 4.2M glucose readers on battery fire risks
Readers for Abbott’s FreeStyle Libre glucose monitoring systems could catch fire if improperly stored or charged, the FDA says.
By Peter Green • Updated April 7, 2023 -
Permission granted by Tidepool
Deep DiveGrassroots innovation: How a patient-driven device for diabetes won FDA clearance
Tidepool Loop, an automated insulin dosing app based on one developed by the DIY diabetes community, received FDA clearance in January.
By Elise Reuter • April 3, 2023 -
Permission granted by Nevro
Q&AFriday Q&A: Nevro CMO tells how the spinal device maker will defend its turf in diabetic pain relief
Dr. David Caraway says Nevro’s device stands apart from competing treatments for painful diabetic neuropathy with its clinical data and approach. The company is also launching a new product.
By Elise Reuter • March 31, 2023 -
Chinnapong via Getty Images
In a threat to diabetes tech market, scientists use implanted glucose-run fuel cell to power insulin release
If commercialized, the technology could disrupt continuous glucose monitor and insulin pump markets fought over by companies including Abbott and Medtronic.
By Nick Paul Taylor • March 29, 2023 -
ClarkandCompany via Getty Images
Senseonics grows sales in Q4 despite ‘softer demand’ for CGM implant in US and Germany
Demand in the U.S. was affected by “a little bit of ambiguity on pricing” ahead of a change to Medicare.
By Nick Paul Taylor • March 17, 2023 -
Courtesy of Tandem Diabetes
Tandem, targeting Medtronic and Insulet’s turf, links artificial pancreas to improved outcomes in kids
If Tandem can prove to regulators that the system can help manage young children’s diabetes, it could compete with Medtronic and Insulet, which have devices that are indicated for use in kids as young as two years.
By Nick Paul Taylor • March 16, 2023 -
Novo Nordisk follows Lilly in sharply cutting price of insulin drugs
Responding to policy changes and pressure over high drug costs, the drug maker is reducing the sticker price of four branded diabetes medicines by up to 75%.
By Delilah Alvarado • March 14, 2023 -
Courtesy of Insulet Corp.
Insulet to join S&P 500 after Silicon Valley Bank ousted
Shares of the insulin pump maker rose Monday on news that it would join the stock index.
By Elise Reuter • March 13, 2023 -
Permission granted by Abbott Laboratories
Abbott CGMs cleared to integrate with automated insulin delivery systems
The regulatory decision allows the devices to be used in artificial pancreas systems, and positions Abbott as a competitor to Dexcom in the space.
By Elise Reuter • March 6, 2023 -
Permission granted by MedCrypt
Q&AFriday Q&A: MedCrypt’s Naomi Schwartz on designing cybersecurity for diabetes devices
Schwartz, who helped review the first automated insulin dosing system, talks about balancing patient access and device security.
By Elise Reuter • March 3, 2023 -
Courtesy of Dexcom
Medicare to expand CGM coverage to more Type 2 diabetes patients
The updated policy could double the market for continuous glucose monitors, and will take effect in April.
By Elise Reuter • Updated March 2, 2023
Previous
